CN107029173A - 一种治疗原发性肝癌的药物组合物 - Google Patents
一种治疗原发性肝癌的药物组合物 Download PDFInfo
- Publication number
- CN107029173A CN107029173A CN201710028395.XA CN201710028395A CN107029173A CN 107029173 A CN107029173 A CN 107029173A CN 201710028395 A CN201710028395 A CN 201710028395A CN 107029173 A CN107029173 A CN 107029173A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- liver
- liver cancer
- leech
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims description 23
- 206010073069 Hepatic cancer Diseases 0.000 title claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 239000003814 drug Substances 0.000 claims abstract description 94
- 241000545744 Hirudinea Species 0.000 claims abstract description 29
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 26
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 26
- 241000218176 Corydalis Species 0.000 claims abstract description 21
- 240000001659 Oldenlandia diffusa Species 0.000 claims abstract description 20
- 241000756943 Codonopsis Species 0.000 claims abstract description 17
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 17
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims description 17
- 240000009138 Curcuma zedoaria Species 0.000 claims description 17
- 235000019509 white turmeric Nutrition 0.000 claims description 17
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims description 16
- 235000014375 Curcuma Nutrition 0.000 claims description 13
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 13
- 244000178320 Vaccaria pyramidata Species 0.000 claims description 2
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims description 2
- 235000019082 Osmanthus Nutrition 0.000 claims 2
- 241000333181 Osmanthus Species 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 244000164480 Curcuma aromatica Species 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 abstract description 50
- 208000014018 liver neoplasm Diseases 0.000 abstract description 49
- 239000000463 material Substances 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 3
- 229940124600 folk medicine Drugs 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 34
- 206010028980 Neoplasm Diseases 0.000 description 28
- 229940079593 drug Drugs 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 21
- 210000002381 plasma Anatomy 0.000 description 21
- 244000163122 Curcuma domestica Species 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 14
- 238000011160 research Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- 206010003445 Ascites Diseases 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 230000002440 hepatic effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 244000131316 Panax pseudoginseng Species 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 102000007625 Hirudins Human genes 0.000 description 6
- 108010007267 Hirudins Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 229940006607 hirudin Drugs 0.000 description 6
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 241000208365 Celastraceae Species 0.000 description 4
- 235000003392 Curcuma domestica Nutrition 0.000 description 4
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 4
- 102100030703 Interleukin-22 Human genes 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 235000000336 Solanum dulcamara Nutrition 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 235000003373 curcuma longa Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 108010074109 interleukin-22 Proteins 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 235000013976 turmeric Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CZIHNRWJTSTCEX-UHFFFAOYSA-N 2 Acetylaminofluorene Chemical compound C1=CC=C2C3=CC=C(NC(=O)C)C=C3CC2=C1 CZIHNRWJTSTCEX-UHFFFAOYSA-N 0.000 description 3
- 241000510654 Bupleurum chinense Species 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 241000783421 Corydalis saxicola Species 0.000 description 3
- 241000876833 Emberizinae Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 3
- 240000008397 Ganoderma lucidum Species 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 3
- 244000153955 Reynoutria sachalinensis Species 0.000 description 3
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- KDPFMRXIVDLQKX-ISGXEFFDSA-N (+)-Curdione Natural products CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)/CC1=O KDPFMRXIVDLQKX-ISGXEFFDSA-N 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241000202726 Bupleurum Species 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- KDPFMRXIVDLQKX-NHFJXKHHSA-N Germacr-1(10)-ene-5,8-dione Chemical compound CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)\CC1=O KDPFMRXIVDLQKX-NHFJXKHHSA-N 0.000 description 2
- 241001646826 Isodon rubescens Species 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 235000003283 Pachira macrocarpa Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241001165494 Rhodiola Species 0.000 description 2
- 241000951473 Schizonepeta Species 0.000 description 2
- 235000014364 Trapa natans Nutrition 0.000 description 2
- 240000001085 Trapa natans Species 0.000 description 2
- 241000830536 Tripterygium wilfordii Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- KDPFMRXIVDLQKX-UHFFFAOYSA-N curdione Natural products CC(C)C1CC(=O)C(C)CCC=C(C)CC1=O KDPFMRXIVDLQKX-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229930187479 gypenoside Natural products 0.000 description 2
- 210000005161 hepatic lobe Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002480 immunoprotective effect Effects 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000009165 saligot Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000015398 thunder god vine Nutrition 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241000031023 Amana edulis Species 0.000 description 1
- 241000209134 Arundinaria Species 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 241000213015 Bupleurum scorzonerifolium Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 235000001938 Citrus medica Nutrition 0.000 description 1
- 235000002555 Citrus medica var sarcodactylis Nutrition 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 241000357628 Codonopsis pilosula subsp. tangshen Species 0.000 description 1
- 241000357631 Codonopsis pilosula var. modesta Species 0.000 description 1
- 241000614989 Codonopsis thalictrifolia Species 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 241000594394 Hedyotis Species 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 235000016551 Potentilla erecta Nutrition 0.000 description 1
- 240000000103 Potentilla erecta Species 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 241000270273 Ptyas dhumnades Species 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 241001482311 Trionychidae Species 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000964941 Whitmania Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000009916 Yoshida Sarcoma Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000006706 cellular oxygen consumption Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000637 radiosensitizating effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 239000008492 tangshen Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000010681 turmeric oil Substances 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种针对肝癌的发病机理进行综合调节,抑制肝癌的少数民族中药配方。本发明是由发明人在广西壮族民间医药的基础上,对传统壮族医药理论及中医药理论进行研究,进行长期的临床应用验证,有较好的治疗效果。该配方由以下重量份数的药物原料制成的:桂莪术10‑15份;白花蛇舌草20‑30份;岩黄连15‑30份;绞股蓝15‑30份;柴胡6‑12份;党参15‑30份;薏苡仁15‑30份;水蛭3‑10份。
Description
技术领域
本发明涉及一种药物组合物,尤其是一种治疗原发性肝癌的药物组合物。
背景技术
原发性肝细胞癌(hepatocellular carcinoma,HCC,下面简称肝癌)是一种常见的恶性肿瘤,高转移和易复发的特性是导致患者病死率高的重要原因,严重危害着人类健康。全世界每年新发肝癌病例约62万人,其中55%在我国,其发病率约为30.3/10万,每年约有14万人死于原发性肝癌[1]。
目前认为肝癌的发生发展多由遗传和环境因素相互作用,多诱因、多基因参与、多步骤调控的复杂过程。现代中医学认为,为肝癌是由于机体正气不足,脏腑功能失调,导致气滞、血瘀、毒聚而形成。总的来说,肝癌脏腑定位于肝脾,在其发生发展中肝郁脾虚为启动因素,络脉瘀阻为重要环节,气滞、血瘀、湿毒相互胶结为病理基础,重点在于“虚”与“瘀”。肝癌乃本虚标实,全身属虚,局部属实。肝癌初期邪实正虚,虚实夹杂,晚期正气亏损,湿热毒邪内蕴,而致气血阴阳进一步受损,以虚证为主。目前手术治疗仍是早期肝癌首选的治疗方法,但我国肝癌患者被诊断时多已处于进展期或晚期,同时伴随着血行转移和癌栓形成,其治疗手段非常有限。直接导致我国肝癌术后五年生存率与欧美发达国家相比处于较低的水平。因此,多学科综合治疗是目前最有效的治疗模式。近年来中医药治疗(包括民族医药)在防治肝癌方面取得了一定的疗效,成为我国多学科综合治疗的重要组成部分。因此,实现肝癌的早期诊断及提高晚期肝癌的疗效尤其迫切。寻找有效的抗肿瘤药物与方法,是世界医学界的重要研究课题。研究表明许多中药具有抗肿瘤作用,尤其是复方,具有多种作用成分和通过多种作用途径产生防治肝癌的作用。近年来一些医学机构和医务工作者发表了较多利用中草药或民族药治疗抑制肝癌的公开文献报道,例如:
1、中国专利,申请号:201410687244.1申请日:2014.11.25名称:一种治疗原发性肝癌的药物及其制备方法,公开(公告)号:104352870A,公开(公告)日: 2015.2.18,申请(专利权)人:孟祥文,李兆沛。地址:山东省立医院。发明(设计)人:孟祥文,李兆沛。摘要:该发明公开了一种治疗原发性肝癌的药物。它由下述原料药制成:党参、黄芪、紫河车、白芍、枸杞子、柴胡、佛手、水飞蓟、金钱草、玉米须、陈皮、白术、枳壳、当归、延胡索、红花、丹参、鳖甲、白花蛇舌草、半枝莲、夏枯草、蒲公英、山慈菇、青皮、昆布、没药和甘草。本发明药物以纯中药组方,毒副作用小,可以改善中晚期原发性肝癌患者的生活质量,延长其存活期,并可以治愈早期原发性肝癌。以本发明药物治疗原发性肝癌,总有效率为100%。
2、中国专利,申请号:201510250551.8申请日:2015.05.14名称:治疗原发性肝癌的中药,公开(公告)号:104857151A,公开(公告)日:2015.8.26,申请(专利权)人:奉化科创科技服务有限公司,地址:315517浙江省奉化市松岙镇后山村后山畈85号。发明(设计)人:励彩玲。摘要:本发明涉及一种治疗肿瘤的药物,尤其涉及一种以植物中草药为原料制成治疗原发性肝癌的中药。一种治疗原发性肝癌的中药,由下述重量比的原料药组成:草河车10~20份、冬凌草5~15份、枯矾10~20份、黄芪10~20份、红景天10~20份、人参5~ 10份、灵芝5~10份、山栀子5~15份、穿心莲5~10份、虎杖25~40份、小叶买麻滕15~25份、雷公藤5~10份、半枝莲5~15份、白花蛇草5~10份、柴胡10~20份、菱角壳10~15份、三七10~20份、白英10~15份。本发明的治疗原发性肝癌的中药为经过多年临床试验总结而得,主用虎杖、冬凌草、白英、枯矾抑制癌细胞生长同时消除肝癌发病的病因,辅以灵芝、人参、甘草、黄芪固本培元,配合其他药物清热解毒,能有效缓解治愈肝癌肿瘤的症状。
中国专利,申请号:201510570027.9申请日:2015.9.06名称:治疗原发性肝癌的中药,公开(公告)号:105106421A,公开(公告)日:2015.12.02,申请 (专利权)人:奉化科创科技服务有限公司,地址:315517浙江省奉化市松岙镇后山村后山畈85号。发明(设计)人:励彩玲:本发明涉及一种治疗肿瘤的药物,尤其涉及一种以植物中草药为原料制成治疗原发性肝癌的中药。一种治疗原发性肝癌的中药,由下述重量份的原料药组成:苍术10~20份、防风5~15份、枯矾10~20份、黄芪10~20份、红景天10~20份、人参5~10份、灵芝5~ 10份、山栀子5~15份、穿心莲5~10份、虎杖25~40份、小叶买麻滕15~25 份、雷公藤5~10份、乌梢蛇5~15份、荆芥5~10份、柴胡10~20份、菱角壳10~15份、三七10~20份、白英10~15份。本发明的治疗原发性肝癌的中药为经过多年临床试验总结而得,主用虎杖、三七、白英、枯矾抑制癌细胞生长同时消除肝癌发病的病因,辅以灵芝、人参、甘草、黄芪固本培元,并以防风、荆芥做调和配合其他药物清热解毒,能有效缓解治愈肺癌肿瘤的症状。
上述公开文献报道的中药能够从中医的角度进行治疗,在治疗肝癌方面有一定的效果。但是有的组方较复杂,有的仅仅在试验阶段,应用时间短,也没有进行实验研究,临床上也没有进行大样本的临床研究,尚有待于临床验证。
发明内容
为达到此目的,本发明人对传统壮医药理论及中医药理论进行研究,在广西壮族民间医药的基础上,进行长期的临床应用验证,并进行动物试验,通过补充和修改。开发出一种针对肝癌的发病机理进行综合调节,抑制肝癌的壮药。
广西是壮族聚居的地区,壮族先民在长期的生活生产实践和同疾病斗争的过程中,积累了丰富的运用本地草药资源治疗肿瘤的经验。近年来,在社会各界的共同努力下,壮医药研究取得了显著性进展。壮医药治疗肿瘤的研究也取得了可喜的进步。多种壮药提取物以及壮药组成的独特方剂、复方成药在防治肝癌的临床和实验研究中取得良好的效果。本发明人经过多年临床和实验研究,也总结到一种能够抑制肝癌的壮药为主的方剂。
本发明抗肿瘤的壮药(中药制剂)的有效成分是由以下重量份数的药物原料制成的:
桂莪术10-15份;白花蛇舌草20-30份;
岩黄连15-30份;绞股蓝15-30份;柴胡6-12份;
党参15-30份;薏苡仁15-30份;水蛭3-10份;
据中药文献记载,以上所说的壮药/中药各成份的来源是:
桂莪术:本品为睡莲科植物莲NelumbonuciferaGaertn.的干燥花托。符合《中国药典》2015版第一部274页莪术项下有关规定。投料前除去杂质,略泡,洗净,蒸软,切厚片,干燥。
白花蛇舌草:本品为茜草科耳草属植物白花蛇舌草 HedyotisdiffusaWilld.[Oldenlandiadiffusa(Willd.)Roxb.]的全草。符合《中国药典》 2015版第一部白花蛇舌草项下有关规定。投料前除去杂质和泥土,晒干。
岩黄连:为罂粟科植物石生黄连的全草。Corydalis saxicola Bunting[C.thalictrifolia Franch.nonJameson ex Regel]的全草。符合《中华本草》岩黄连项下有关规定。投料前除去杂质,洗净,晒干。
绞股蓝:绞股蓝属草质攀援植物;茎细弱,具分枝,具纵棱及槽,无毛或疏被短柔毛Gynostemmapentaphyllum(Thunb.)。符合新药转正标准第54册14页绞股蓝项下有关规定投料前取原药材,除去杂质,洗净,稍润,切段。干燥。贮干燥容器内,置通风干燥处。
柴胡:本品为伞形科植物柴胡Bupleurumchinense DC.或狭叶柴胡Bupleurumscorzonerifolium Willd.的干燥根。按性状不同,分别习称“北柴胡”和“南柴胡”。符合中国药典2015年版一部280页柴胡项下有关规定。投料前北柴胡除去杂质和残茎,洗净,润透,切厚片,干燥。南柴胡除去杂质,洗净,润透,切厚片,干燥。
党参:本品为梧梗科植物党参Codonopsispilosula(Franch.)Nannf.、素花党参Codonopsispilosula Nannf.var.modesta(Nannf.)L.T.Shen或川党参Codonopsistangshen Oliv.的干燥根。符合中国药典2015年版一部281页党参项下有关规定。投料前除去杂质,洗净,润透切厚片,干燥。
薏苡仁:本品为禾本科植物薏苡Coix lacryma-jobi L.var.mayuen(Roman.)Stapf的干燥成熟种仁。符合中国药典2015年版一部376 页薏苡仁项下有关规定。投料前除去杂质。
水蛭:本品为水經科动物蚂蟥W/i&mcznia pigra Whitman、水経Hirudonipponica Whitman或柳叶蚂横W/iifmama acranulata Whitman的干燥全体。符合中国药典2015年版一部83页水蛭项下有关规定。投料前洗净,切段,干燥。
本发明壮药的方解:
壮医方义:本发明由桂莪术、白花蛇舌草、水蛭、绞股蓝、岩黄连等壮药组成。本方可用于湿热瘀毒阻滞,龙路不通,谷道不调,聚结而成之肝癌。白花蛇舌草、桂莪术通龙路除瘀血抗肿瘤,可为主药。岩黄连、薏苡仁苦寒清湿热散瘀肿为母药,柴胡理气散结,绞股蓝通调三道两路可为帮药。党参防诸药耗气伤血,薏苡仁健脾祛湿,水蛭善走龙路为带药。
本发明的药物抗肝癌的机理如下:
桂莪术:1.抗肿瘤作用:莪术油制剂在体外对小鼠艾氏腹水癌细胞、615纯系小鼠的L615白血病及腹水型肝癌细胞等多种瘤株的生长有明显抑制和破坏作用。100%阿莪术注射液0.3-0.5ml给小鼠腹腔注射,对肉瘤S180。有较好的疗效,抑瘤率达50%以上。从莪术挥发油中得到的单体,莪术醇和莪术二酮75mg/kg 皮下注射时,对小鼠肉瘤S37,宫颈癌U14、艾氏腹水癌(ECA)均有较高的抑制率,肿瘤明显缩小者,可见瘤组织周围纤维细胞增多,内有一层淋巴细胞、吞噬细胞包围肿瘤细胞等免疫反应出现。在电镜下,治疗组肿瘤细胞表现核质比例减少,核外形趋向正常,染色质、核仁和染色质间颗粒数量减少,故认为莪术对小鼠肉瘤的细胞核代谢有抑制作用。体外试验证明莪术醇及莪术二酮对艾氏腹水癌细胞有明显破坏作用,能使其变性坏死。不同浓度的莪术油注射液对瘤细胞均有明显的直接破坏作用,有作用快而强的特点,瘤细胞数越多,杀灭90%的瘤细胞所需的药液浓度就越大。莪术抗癌作用的方式既有直接作用,也有宿主的免疫反应参与。临床以莪术油作瘤内注射治疗宫颈癌,治疗后可见瘤组织坏死脱落,局部淋巴细胞浸润,部分病例肿块消失,宫颈光滑,提示莪术有直接杀瘤细胞的作用。在病理切片中则见到有密集的小淋巴细胞围绕癌细胞,淋巴窦中有大量的窦细胞组织增殖,血液中淋巴细胞有显着的升高,这些均提示有效病例中宿主有明显的免疫反应。莪术抗癌作用的原理,莪术油除能直接杀瘤作用外,还能增强瘤细胞免疫原性,从而诱发或促进机体对肿瘤的免疫排斥反应,实验证明用莪术处理的ECA及L615。瘤苗进行主动免疫,确实能使部分动物获得明显的保护效应。进一步研究证明莪术L615瘤株的主动免疫保护效应具有一定的特异性,因为经莪术处理的L615瘤免疫的动物,不能产生对L795(是615系小鼠的一株新的肉瘤白血病)的交叉免疫保护效应。一些对L615具有明显免疫力的莪术瘤苗免疫组动物,尽管能耐受10(-3)×10个L615细胞的多次攻击,却死于3×10 个L759瘤细胞。且这种免疫保护效应具有一定的稳定性,一旦建立后,能够维持相当长(10-13个月)的时间,但不能传给子代,因为其子代绝大多数(93/ 94)不能耐受105-3×105个L615细胞的攻击,均发生典型的L615,白血病而死亡,平均存活时间也未见延长、说明亲代的这种免疫保护效应是后天获得而不能传给子代。用纯系雌性T-739小鼠观察莪术油对肺腺癌(LA-795)的放射增敏作用,实验结果证明,用莪术油腹腔注射加照射组比单纯照射组有明显的肿瘤生长延迟效果,可使放射治疗效果提高42%,达到中等增敏作用。
白花蛇舌草:1.抗肿瘤作用:在体外(相当生药6g/ml)对急性淋巴细胞型、粒细胞型、单核细胞型以及慢性粒细胞型的肿瘤细胞有较强抑制作用(美蓝试管法);用瓦氏呼吸器测定,对前二者的抑制作用亦较强。曾用浸膏于小鼠S-180和艾氏腹水癌,以及大鼠吉田肉瘤的实验性治疗,皆无明显抗癌作用;0.5-1g生药/ml 在体外对吉田肉瘤和艾氏腹水癌有抑制(美蓝试管法),但作者认为此属非特殊性的。
岩黄连:抗肿瘤作用腹腔注射岩黄连总碱200mg·kg-1,在体内对移植性动物肿瘤有一定的抑制作用。研究岩黄连对癌细胞呼吸的影响时发现,岩黄连对小鼠艾氏腹水癌(EAC)、小鼠肉瘤180(S-180)和小鼠肝癌腹水(HAC)的细胞代谢有明显抑制作用,且抑制癌细胞耗氧方面比5-氟尿嘧啶作用强,其中S-180对岩黄连的作用最为敏感,而HAC稍差。证明岩黄连总碱对以上3种肿瘤细胞的体外代谢确有一定的抑制作用。
绞股蓝:经研究证明,绞股蓝总皂苷对肿瘤细胞的生长具有明显的抑制作用并有直接杀灭癌细胞的作用。增强患者T淋巴细胞免疫功能的作用,用于防治恶性肿瘤,符合“虚则补之”的治疗原则。
柴胡:柴胡多糖、柴胡热水提取物(高分子组分)等能促进机体免疫功能。柴胡多糖可增加库弗(Kupffer)细胞吞噬功能,增强自然杀伤细胞的功能,提高病毒特异抗体滴度,提高淋巴细胞转化率和皮肤迟发型超敏反应
党参:对免疫机能的影响:党参及其多糖可使巨噬细胞的数量增加,细胞体积增大,伪足多,吞噬能力增强;细胞内的DNA、RNA、糖类、ACP酶、ATP 酶、酸性酯酶和琥珀脱氢酶活性均显著增强,经显微分光光度计测定,服药后,巨噬细胞内各种化学成分含量明显增加,与对照组呈显著性差异。党参还能明显促进ConA活化的淋巴细胞DNA和蛋白质的生物合成,促进DNA合成的最适浓度为100μg/ml。DNA合成的高峰在48小时,对白介素-2(IL-2)产生也有明显的增强作用。
薏苡仁:有报告称薏苡仁对癌细胞有阻止成长及伤害作用。临床上的“康莱特”注射液就是薏苡仁油提取物,在临床广泛应用,获得较好疗效。
水蛭:抗凝血作用:水蛭水提物0.45g/kg灌胃后4h及连续灌胃7天,对ADP 诱导的大鼠血小板聚集均有显著的抑制作用,且能降低全血比粘度和血浆比粘度,缩短红细胞电泳时间;体外法试验,水蛭水提物200mg/ml、100mg/ml及 50mg/ml对健康人血小板聚集也有显著的抑制作用。水蛭素是凝血酶抑制剂,每毫克水蛭素含10~400抗凝血酶单位的活性;水蛭素对细菌内毒素引起的大鼠血栓形成有预防作用,并能减少大鼠的死亡率;水蛭素还能对抗凝血酶所致的离体蛙心收缩力增强作用。
附图说明
图1为实施例6中,MTT法实施例1含药血浆与空白血浆的对照实验。
图2为实施例6中,MTT法水蛭素含药血浆与空白血浆的对照实验。
图3为实施例6中,MTT法绞股蓝含药血浆与空白血浆的对照实验。
具体实施方式
实施例1
一种治疗肝癌的药物。由以下重量份数有效成分的壮药材原料制成:桂莪术 15g;白花蛇舌草30g;岩黄连30g;绞股蓝30g;柴胡12g;党参30g;薏苡仁 30g;水蛭6g;
配制及服用方法:水煎煮,每日1剂,分两次早晚服用。1个月为1个疗程。
实施例2
一种治疗肝癌的药物。由以下重量份数有效成分的壮药材原料制成:桂莪术 10g;白花蛇舌草20g;岩黄连15g;绞股蓝15g;柴胡6g;党参15g;薏苡仁15g;水蛭3g。
该药物组合物按照常规生产工艺,加入辅料制成颗粒剂。
实施例3
一种治疗肝癌的药物。由以下重量份数有效成分的壮药材原料制成:桂莪术 13g;白花蛇舌草28g;岩黄连19g;绞股蓝22g;柴胡11g;党参24g;薏苡仁 19g;水蛭10g;
该药物组合物按照常规生产工艺,加入辅料制成片剂。
实施例4
一种治疗肝癌的药物。由以下重量份数有效成分的壮药材原料制成:桂莪术15g;白花蛇舌草30g;岩黄连30g;绞股蓝30g;柴胡12g;党参30g;苡仁30g;水蛭8g;
该药物组合物按照常规生产工艺,加入辅料制成胶囊。
实施例5
一种治疗肝癌的药物。由以下重量份数有效成分的壮药材原料制成:桂莪术 12g;白花蛇舌草26g;岩黄连21g;绞股蓝30g;柴胡7g;党参18g;薏苡仁30g;水蛭10g。
该药物组合物按照常规生产工艺,加入辅料制成口服液。
实施例6
一种治疗肝癌的药物。由以下重量份数有效成分的壮药材原料制成:桂莪术 15g;白花蛇舌草30g;岩黄连30g;绞股蓝30g;柴胡12g;党参15g;薏苡仁30g;水蛭9g。
配制及服用方法:水煎煮,每日1剂,分2次服,早晚各1次。水蛭,速冻后研粉,装胶囊,早晚各服1次,每次3g。(用上述中药送服)。1个月为1个疗程。
本发明采用实施例1的配方、配方中属驱邪性质的药物组合(简称拆方包含:莪术15g,白花蛇舌草30g,岩黄连30g,绞股蓝30g,水蛭6g)及水蛭、绞股蓝作为研究对象,其抗肝癌的体外细胞实验研究如下:
获取实施例1配方,拆方,水蛭,绞股蓝含药血清及血浆:在我们实验中,将SD大鼠分为两组低剂量组合高剂量组,灌胃复方,拆方,水蛭,绞股蓝。一周后取其血清及血浆,得到复方,拆方,水蛭,绞股蓝的含药血清及含药血浆。之后过滤,灭活,备用。
蛭岩方抗癌作用研究:我们采用MTT法通过对复方含药血清以及含药血浆干预了h22肝癌细胞增殖实验。如图所示,研究结果表明复方含有血浆对肿瘤细胞有细胞的增殖有一定的抑制作用。(组别1为空白对照组,下同;组别2实施例1含药血浆干预组)
拆方抗癌作用研究:我们采用MTT法进行拆方含药血浆和复方含药血浆对肝癌细胞H22的对比研究。结果是拆方含药血浆和复方含药血浆之间作用效果差异不大。说明复方的有效成分可能来自拆方之中的药物。
水蛭抗癌作用研究:方法同复方研究。结果如图所示,结果提示水蛭含药血清对肝癌细胞的抑制增殖作用不明显,含药血浆作用较明显。这符合复方的研究结果。同时我们课题组前期实验证明水蛭素对肝癌细胞有明显抑制作用。这表明含药血浆中有效成分比含药血清多有关。
绞股蓝抗癌作用研究:方法同水蛭研究。结果含药血浆有一定的抑制肝癌细胞增殖作用。说明绞股蓝皂苷对肝癌细胞有一定抑制的作用。
本发明的体外动物实验:
实验用雄性SD大鼠80只,按抽签法随机分为4组(大、小剂量中药组及模型组、空白组),每组20只。除空白组正常饲养外,其余3组均用DEN作为肝癌的启动剂(200μg/kg),然后喂食含0.015%的2-乙酰氨基芴(2-AAF) 饲料2周,行大部分肝切除术。大、小剂量中药组大鼠从实验开始即加用本发明 (实施方案1)的中药水煎剂灌胃,模型组则单纯喂食基础饲料。于停饲2-AAF 饲料3d后抽取大鼠血液并将其处死,检测大鼠血清白介素2(IL-2)含量,肝脏按规定部位取材,ABC法行转化生长因子β1(TGF-β1)免疫组织化学染色,另外肝脏采用γ-谷氨酰转肽酶(γ-GT)染色,算出平均每平方厘米肝面积中γ-GT阳性灶的数量、面积。
结果:大、小剂量中药组γ-GT阳性灶的数量、面积均明显少于模型组(P <0.05),大、小剂量中药组间无明显差异(P>0.05)。免疫组化检测显示小剂量中药组TGF-β1阳性率较模型组低(P<0.05),大剂量中药组TGF-β1 阳性率低于模型组,但差异无统计学意义(P>0.05)。大剂量中药组、小剂量中药组、模型组大鼠血清IL-2含量均较空白组降低(P<0.05),大剂量中药组、小剂量中药组降低程度较模型组低(P<0.05),大剂量中药组、小剂量中药组 IL-2含量无显著差异(P>0.05)。
结论:我们认为本发明药物组合水煎液对大鼠肝癌前病变有一定的预防作用,作用机制可能是通过抑制TGF-β1的生成,减轻大鼠的免疫抑制,相对提高大鼠机体免疫功能,从而抑制肝癌前病变。说明本发明有防治大鼠肝癌的作用。
通过上述的含药血清及血浆对肝癌细胞的抑制作用及对大鼠有肝癌前病变抑制作用,说明本发明实施例1的配方制备的水煎液及拆方莪术15g;白花蛇舌草30g;岩黄连30g;绞股蓝30g,水蛭6g;水蛭、绞股蓝均有不同程度的抑制肝癌细胞的作用。动物体内试验结果进一步证实了本发明对肝癌前病变的抑制作用,从而说明本发明对肝癌有防治作用。本发明采用的药物为天然动植物的壮药为主,符合国家药政法规定,以壮医药及中医药治疗肝癌机理及现代药理研究为原则,利用其综合作用,达到治疗肝癌目的。对人体无毒副作用。
一、本发明临床观察的结果如下:
1、诊断标准
参照我国卫生部医政司编《原发性肝癌诊疗规范》第(2011年版)。
2、病例纳入标准
符合原发性肝癌诊断标准。属临床BCLC C期患者;有明确的肿瘤测量病灶。
肝癌患者;预计生存在3个月以上者;年龄在18-70岁的患者,排除孕妇及哺乳期妇女。
2011年1月至2015年12月期间。总病例人数120人,其中男87人,女 33人;
3、试验方法:
患者服用本发明实施例5制得的汤剂,一个月为一个疗程,用药两个疗程或以上;全部患者同时按病情需要予护肝、止痛、利尿等常规治疗。
4、疗效判定标准:
按实体瘤RECIST 1.1疗效评价标准。疗效分完全缓解(CR),部分缓解(PR),稳定(SD),进展(MR)。
5治疗结果:CR 3例(2.5%),PR 23例(27.5%),SD 41例(34.2%),MR 53例(44.2%)。
由上述治疗结果可以看出,本发明的治疗原发性肝癌的中药能够有效缓解或治愈部分肝癌。
二、典型病例
病例1,杜某,男,75岁。患者具有乙肝病史30余年,因肝区胀痛不适3 个月入院,CT检查发现为“肝右叶肝癌,大小约3*2cm,伴有肝硬化,脾大。 AFP 403ng/L。肝功能正常。诊断为:1、原发性肝癌2、肝硬化。因患者不愿手术治疗,转求中医药治疗,以服用本发明实施例1制备的方剂煎液为主,配合抗乙肝、止痛等治疗,服用3个半月,复查CT提示肝右叶肿瘤消失,AFP降至23ng/。随访14个月无复发。
病例2,黄某某,男,42岁。因右上腹疼痛伴腹胀、纳差1个月,于2016年 4月入院。经腹部CT检查发现肿瘤大小为6×3cm,位于肝左右叶之间。伴门脉右支癌栓。中等腹水。AFP560ng/L,有乙肝病史20年。肝功能:AST 78U/L, ALT108U/L,白蛋白28g/L。
诊断:1、原发性肝癌(BCLC C期);2、肝硬化。无手术、介入治疗指征,因经济困难,不愿意采用靶向治疗。转来以中医为主治疗。以本发明实施例1 制备的水煎液口服为主,结合补充白蛋白,止痛,利尿,护肝等基础治疗半个月,出院后以本发明水煎液口服,每天一次。2016年6月16日来院复查,CT提示肝内肿物缩小,腹水消失,AFP下降至102ng/L,肝功正常。患者饮食较前好,腹胀痛减轻,不需要服止痛药。患者至今仍在随防中。
上述只是本发明的较佳实施例,并非对本发明作任何形式上的限制。虽然本发明已以较佳实施例做了充分公开,然而并非用以限定本发明。因此,凡是未脱离本发明技术方案的内容,依据本发明技术实质对以上实施例所做的任何简单修改、等同变化及修饰,均应落在本发明技术方案保护的范围内。
Claims (2)
1.一种治疗原发性肝癌的药物组合物,其特征在于,由以下重量比组分的药物组成:桂莪术10-15 份;白花蛇舌草20-30 份;岩黄连15-20 份;绞股蓝15-30份;柴胡6-12 份;党参15-30份;薏苡仁15-30份;水蛭3-10份。
2.如权利要求1所述的药物组合物,其特征在于,由以下重量比组分的药物组成:桂莪术15份;白花蛇舌草30份;岩黄连30份;绞股蓝30份;柴胡12份;党参30份;薏苡仁30份;水蛭6份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710028395.XA CN107029173B (zh) | 2017-01-16 | 2017-01-16 | 一种治疗原发性肝癌的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710028395.XA CN107029173B (zh) | 2017-01-16 | 2017-01-16 | 一种治疗原发性肝癌的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107029173A true CN107029173A (zh) | 2017-08-11 |
CN107029173B CN107029173B (zh) | 2020-09-15 |
Family
ID=59530779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710028395.XA Expired - Fee Related CN107029173B (zh) | 2017-01-16 | 2017-01-16 | 一种治疗原发性肝癌的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107029173B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107468949A (zh) * | 2017-09-30 | 2017-12-15 | 广西壮族自治区肿瘤防治研究所 | 治疗晚期原发性肝癌的中药组合物及其制备方法 |
CN110974922A (zh) * | 2019-11-29 | 2020-04-10 | 汤耀清 | 一种治疗肝癌的中药组合物、药物及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102247479A (zh) * | 2011-06-03 | 2011-11-23 | 广西壮族自治区民族医药研究院 | 一种抗肿瘤壮药及其制备方法 |
CN103908636A (zh) * | 2014-04-07 | 2014-07-09 | 陈大刚 | 对原发性肝细胞癌和门静脉癌栓进行治疗的复方中药制剂 |
US20160000856A1 (en) * | 2014-07-02 | 2016-01-07 | Hsiu-Hsien Tsai | Composition for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs |
CN106267003A (zh) * | 2016-09-22 | 2017-01-04 | 深圳市中医院 | 一种芪术抗癌中药组合物 |
-
2017
- 2017-01-16 CN CN201710028395.XA patent/CN107029173B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102247479A (zh) * | 2011-06-03 | 2011-11-23 | 广西壮族自治区民族医药研究院 | 一种抗肿瘤壮药及其制备方法 |
CN103908636A (zh) * | 2014-04-07 | 2014-07-09 | 陈大刚 | 对原发性肝细胞癌和门静脉癌栓进行治疗的复方中药制剂 |
US20160000856A1 (en) * | 2014-07-02 | 2016-01-07 | Hsiu-Hsien Tsai | Composition for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs |
CN106267003A (zh) * | 2016-09-22 | 2017-01-04 | 深圳市中医院 | 一种芪术抗癌中药组合物 |
Non-Patent Citations (2)
Title |
---|
杜琴等: "补益中药抗肝癌作用研究概况", 《中药材》 * |
柯珉珉等: "岩黄连有效成分的研究", 《植物学报》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107468949A (zh) * | 2017-09-30 | 2017-12-15 | 广西壮族自治区肿瘤防治研究所 | 治疗晚期原发性肝癌的中药组合物及其制备方法 |
CN107468949B (zh) * | 2017-09-30 | 2020-10-30 | 广西壮族自治区肿瘤防治研究所 | 治疗晚期原发性肝癌的中药组合物及其制备方法 |
CN110974922A (zh) * | 2019-11-29 | 2020-04-10 | 汤耀清 | 一种治疗肝癌的中药组合物、药物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN107029173B (zh) | 2020-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03003446A (es) | Nueva composicion herbacea medicinal para tratar enfermedades del higado y vih. | |
CN102727686B (zh) | 一种治疗脂肪肝中药组合物 | |
CN110787233B (zh) | 保肝中药组合物及其提取物和制药用途 | |
CN103055285B (zh) | 治疗早期肝硬化的中药及其制备方法 | |
CN104436065A (zh) | 一种影像科用治疗或预防造影剂肾病的中药及制备方法 | |
CN103223069A (zh) | 一种治疗肝炎的中药组合物 | |
CN104436009A (zh) | 肝癌药 | |
CN107029173A (zh) | 一种治疗原发性肝癌的药物组合物 | |
CN103405582A (zh) | 改善类风湿关节炎关节肿痛的中药组合物 | |
CN104524441A (zh) | 治疗脂肪性肝炎合并高脂血症的中药组合物及其制备方法 | |
CN107334798A (zh) | 树参提取物及制法及在治疗类风湿性关节炎病药物中的应用 | |
CN104547902A (zh) | 中药制剂用于制备治疗慢性肠炎、阑尾炎药物中的用途 | |
CN106039109A (zh) | 防治寒湿阻络型的类风湿性关节炎的中药药酒 | |
CN101698085B (zh) | 一种治疗肝纤维化或肝硬化失代偿早期的药物组合物及制备方法和用途 | |
CN104547798A (zh) | 一种治疗慢性肠炎、阑尾炎的中药制剂及其制备方法 | |
CN104771589A (zh) | 一种治疗脂肪肝的中药组合物及其应用 | |
CN101703737B (zh) | 一种治疗肝纤维化的中成药 | |
CN104857361A (zh) | 一种治疗黄疸的中药组合物 | |
CN105012552A (zh) | 一种治疗风胜行痹型风湿性关节炎的中药及制备方法 | |
CN103735631B (zh) | 一种治疗乙肝的药物组合物及其制备方法 | |
CN104825817A (zh) | 一种具有抗肿瘤作用的中药制剂 | |
CN107898972A (zh) | 一种用于治疗肝脏疾病的中药组合物及应用 | |
CN103212033B (zh) | 一种治疗病毒性肝炎的药物组合物 | |
CN107184917B (zh) | 一种治疗慢性萎缩性胃炎的中药组合物及其应用 | |
CN105726969A (zh) | 一种治疗急性放射性肺炎的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200915 |
|
CF01 | Termination of patent right due to non-payment of annual fee |